Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cryo-Cell International Inc (CCEL)
NYSE MKT:CCEL
RESEARCH TOOLSreports
Cryo-Cell International (CCEL) Stock Price & Analysis
36 Followers
CCEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.67 - $9.50
Previous Close$7.17
Volume7.33K
Average Volume (3M)8.47K
Market Cap
$57.80M
Enterprise Value$70.87M
Total Cash (Recent Filing)$1.53M
Total Debt (Recent Filing)$14.59M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Oct 11, 2024EPS Estimate
$0.03Last Dividend Ex-Date
Sep 01, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding8,104,477
10 Day Avg. Volume7,734
30 Day Avg. Volume8,473
Standard Deviation0.19
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-5.25
Price to Sales (P/S)9.30
Price to Cash Flow (P/CF)5.50
P/FCF Ratio15.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit3.09
Enterprise Value/Ebitda-6.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Cryo-Cell International News
PremiumPre-Earnings
Is CCEL a Buy, Before Earnings?
PremiumCompany Announcements
Cryo-Cell International Announces Strategic Subsidiary Spin-Off Plans
Bulls Say, Bears Say
Bulls Say
Business ModelHighly attractive business model consisting of mostly recurring revenues, high margins, and positive cash flow generation.
EarningsCryo-Cell International beats F2Q24 EBITDA expectations.
Strategic OpportunitiesThe company is exploring strategic alternatives to spin-off its drug trial and clinic businesses, which are more capital intensive.
Bears Say
Mergers And AcquisitionsReShape Lifesciences announces reverse merger with Vyome Therapeutics and assets sale to Biorad.
Revenue GrowthModest F2Q24 top line growth due to the majority of revenue coming from the mature processing and storage segment and a slowdown in new business units.
Stock RatingReShape Lifesciences stock rating downgraded to Hold as more details are awaited.
---
Ownership Overview
54.80%
Insiders
1.41% Mutual Funds
6.66% Other Institutional Investors
37.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CCEL FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was $3.67 and its highest was $9.50 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Currently, no data Available
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Oct 11, 2024 which is in 80 days.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Jul 15, 2024. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc pays a Notavailable dividend of $0.9 which represents an annual dividend yield of N/A. See more information on Cryo-Cell International Inc dividends here
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is $0.03.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,061,786 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of $0.08 in its last earnings report, beating expectations of $0.05. Following the earnings report the stock price went up 0.843%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in CCEL
---
Cryo-Cell International Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.00%
Trailing 12-Months
Company Description
Cryo-Cell International Inc
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation service and to advance regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage; and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded on September 11, 1989 and is headquartered in Oldsmar, FL.
---
CCEL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering CCEL
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+24.41%
assigned a buy rating 6 days ago
Copying Allen Klee's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.41% per trade.
---